Literature DB >> 22971662

Interleukin-9 release from human kidney grafts and its potential protective role in renal ischemia/reperfusion injury.

Kirsten A Kortekaas1, Dorottya K de Vries, Marlies E J Reinders, Ellen Lievers, Jan Ringers, Jan H N Lindeman, Alexander F M Schaapherder.   

Abstract

OBJECTIVE AND
DESIGN: The pathophysiology of ischemia/reperfusion (I/R) injury is dominated by an inflammatory response. In the identification of new therapeutic agents, the role of individual cytokines may be essential. Interleukin (IL)-9 is a pleiotropic cytokine recently identified to be involved in various immune responses. In this study, the role of IL-9 in renal I/R injury was assessed.
METHODS: We performed repeated direct measurements of arteriovenous IL-9 concentration differences over the reperfused graft in human kidney transplantation.
RESULTS: Substantial renal IL-9 release was observed from deceased donor kidneys (P = 0.006). In contrast, living donor kidneys, which have a more favourable clinical outcome, did not release IL-9 during early reperfusion (P = 0.78). Tissue expression of IL-9 did not change upon reperfusion in both living and deceased human donor kidneys. To assess the role of IL-9 in I/R injury, an experimental study comprising IL-9 inhibition in mice undergoing renal I/R was performed. Although there was no difference in kidney function, structural damage was significantly aggravated in anti-IL-9 treated mice.
CONCLUSIONS: Deceased donor grafts show a substantial IL-9 release upon reperfusion in clinical kidney transplantation. However, inhibition of IL-9 aggravated kidney damage, suggesting a regulating or minor role of IL-9 in clinical I/R injury.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22971662     DOI: 10.1007/s00011-012-0550-7

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  25 in total

1.  Delayed graft function: risk factors and implications for renal allograft survival.

Authors:  A O Ojo; R A Wolfe; P J Held; F K Port; R L Schmouder
Journal:  Transplantation       Date:  1997-04-15       Impact factor: 4.939

2.  Risk factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group.

Authors:  O H Koning; R J Ploeg; J H van Bockel; M Groenewegen; F J van der Woude; G G Persijn; J Hermans
Journal:  Transplantation       Date:  1997-06-15       Impact factor: 4.939

3.  Human P40 T-cell growth factor (interleukin-9) supports erythroid colony formation.

Authors:  R E Donahue; Y C Yang; S C Clark
Journal:  Blood       Date:  1990-06-15       Impact factor: 22.113

4.  Mast cells are essential intermediaries in regulatory T-cell tolerance.

Authors:  Li-Fan Lu; Evan F Lind; David C Gondek; Kathy A Bennett; Michael W Gleeson; Karina Pino-Lagos; Zachary A Scott; Anthony J Coyle; Jennifer L Reed; Jacques Van Snick; Terry B Strom; Xin Xiao Zheng; Randolph J Noelle
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

Review 5.  Cellular sources and immune functions of interleukin-9.

Authors:  Randolph J Noelle; Elizabeth C Nowak
Journal:  Nat Rev Immunol       Date:  2010-09-17       Impact factor: 53.106

6.  Non-heart-beating versus cadaveric and living-donor livers: differences in inflammatory markers before transplantation.

Authors:  Wayel Jassem; Dicken D H Koo; Paolo Muiesan; Lucia Cerundolo; Mohamed Rela; Susan V Fuggle; Nigel D Heaton
Journal:  Transplantation       Date:  2003-04-27       Impact factor: 4.939

7.  Differential expression of T-cell growth factors in rejecting murine islet and human renal allografts: conspicuous absence of interleukin (IL)-9 despite expression of IL-2, IL-4, IL-7, and IL-15.

Authors:  X C Li; A D Schachter; M S Zand; Y Li; X X Zheng; W E Harmon; T B Strom
Journal:  Transplantation       Date:  1998-07-27       Impact factor: 4.939

8.  Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft.

Authors:  D K de Vries; J H N Lindeman; D Tsikas; E de Heer; A Roos; J W de Fijter; A G Baranski; J van Pelt; A F M Schaapherder
Journal:  Am J Transplant       Date:  2009-05-20       Impact factor: 8.086

9.  Human interleukin (IL)-9 specifically stimulates proliferation of CD34+++DR+CD33- erythroid progenitors in normal human bone marrow in the absence of serum.

Authors:  L Lu; T Leemhuis; E F Srour; Y C Yang
Journal:  Exp Hematol       Date:  1992-05       Impact factor: 3.084

10.  Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells.

Authors:  Bettina Haslinger; Robert Kleemann; Karin H Toet; Teake Kooistra
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

View more
  4 in total

Review 1.  IL-9 and Th9 cells in health and diseases-From tolerance to immunopathology.

Authors:  Junhui Li; Shuqiu Chen; Xiang Xiao; Yong Zhao; Wenjun Ding; Xian C Li
Journal:  Cytokine Growth Factor Rev       Date:  2017-07-17       Impact factor: 7.638

2.  Complement Inhibitor CRIg/FH Ameliorates Renal Ischemia Reperfusion Injury via Activation of PI3K/AKT Signaling.

Authors:  Chao Hu; Long Li; Peipei Ding; Ling Li; Xiaowen Ge; Long Zheng; Xuanchuan Wang; Jina Wang; Weitao Zhang; Na Wang; Hongyu Gu; Fan Zhong; Ming Xu; Ruiming Rong; Tongyu Zhu; Weiguo Hu
Journal:  J Immunol       Date:  2018-11-14       Impact factor: 5.422

3.  Amniotic Fluid Derived Stem Cells with a Renal Progenitor Phenotype Inhibit Interstitial Fibrosis in Renal Ischemia and Reperfusion Injury in Rats.

Authors:  Marina Gabriela Monteiro Carvalho Mori da Cunha; Silvia Zia; Fanny Oliveira Arcolino; Marianne Sylvia Carlon; Diego Vilibaldo Beckmann; Ney Luis Pippi; Dominguita Luhers Graça; Elena Levtchenko; Jan Deprest; Jaan Toelen
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

4.  Inhibition of Histone H3K27 Acetylation Orchestrates Interleukin-9-Mediated and Plays an Anti-Inflammatory Role in Cisplatin-Induced Acute Kidney Injury.

Authors:  Wenjuan Jiang; Xinrong Yuan; Hong Zhu; Changsheng He; Caiqiong Ge; Qing Tang; Chuanting Xu; Bingfeng Hu; Cheng Huang; Taotao Ma
Journal:  Front Immunol       Date:  2020-03-03       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.